Glucose B. Braun

Glucose B. Braun is an intravenous solution for injection that contains glucose monohydrate as the sole active ingredient. It is supplied in a sterile aqueous form, marketed in the European Union, and classified as a carbohydrate solution used for fluid and electrolyte replacement. The product provides exogenous glucose to support energy metabolism and maintain plasma glucose levels during medical procedures or when oral intake is not possible.

Glucose B. Braun is indicated for several clinical situations where rapid provision of glucose and fluid balance is required.

- Treatment of hypoglycemia in patients unable to receive oral glucose. - Component of parenteral nutrition regimens to supply calories. - Fluid and electrolyte replacement during dehydration or postoperative care. - Prevention of intra‑operative hypoglycemia in surgical patients. - Support for patients with metabolic disorders requiring controlled glucose infusion.

When administered intravenously, Glucose B. Braun may be associated with a range of observed effects. Most reactions are mild, dose‑related, and resolve after the infusion is completed.

Common: - Mild hyperglycemia that resolves without intervention. - Local irritation or pain at the injection site. - Nausea or transient vomiting. - Fluid overload in patients receiving large volumes. - Transient headache or dizziness. - Mild increase in serum triglycerides.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Electrolyte disturbances such as hyponatremia. - Hypersensitivity reactions including rash, urticaria, or anaphylaxis. - Cardiac arrhythmias secondary to electrolyte shifts. - Acute pulmonary edema in patients with compromised cardiac function. - Renal impairment due to osmotic diuresis.

Glucose B. Braun should be used with attention to patient‑specific factors and clinical conditions that may modify its safety profile.

- Assess blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use caution in individuals with known hypersensitivity to glucose solutions or excipients. - Monitor electrolyte concentrations, especially sodium and potassium, during prolonged therapy. - Avoid concurrent administration with high‑dose dextrose-containing products unless clinically justified. - Ensure aseptic technique to reduce risk of catheter‑related infections.

Glucose B. Braun may interact with other intravenous therapies; awareness of potential interactions helps maintain safe infusion practices.

Avoid: - Co‑administration with other high‑concentration dextrose solutions without adjusting total carbohydrate load. - Simultaneous infusion of potassium chloride in concentrations exceeding recommended limits, which can precipitate. - Mixing with calcium-containing solutions, which can cause precipitation.

Use with caution: - Concurrent use of insulin infusions; glucose may counteract insulin’s glucose‑lowering effect. - Administration with loop diuretics, as rapid fluid shifts can affect electrolyte balance. - Combination with sodium bicarbonate solutions, which may alter serum pH and glucose metabolism. - Concurrent administration of beta‑blockers, which may mask signs of hypoglycemia.